Transgene S.a.

Institut National De La Sante Et De La Recherche Medicale

Genmab A+s

Other

Centre National De La Recherche Scientifique

F. Hoffmann-la Roche Ag

Bioprocess Pty Ltd.

Genevieve Inchauspe

Anne Fournillier

Marc Nasoff

Christian G Trepo

Christian Reiter

Nourredine Himoudi

Marie Parnot

Maria Dimitrova-Tchomakov

Jean-Daniel Abraham

Suzanne Zebedee

Francois Habersetzer

Claude Desgranges

Nathalie Silvestre

Alfred M Prince

Glaucia Paranhos-Baccala

Thierry Delair

Yasemin Ataman-Onal

Perrine Martin

Bernard Verrier

Doris Schmitt

Michael F Nunn

Torsten B Helting

Pascale Jeannin

Ann Fournillier

Laurence Chatel

Alfred S Prince

Nonlamellar bioresorbable microparticles to which protein substances are bonded, and a method for preparing the microparticles, comprising: (i) preparing the microparticles from at least one bioresorbable polymer without stabilizer and without surfactant; and (ii) bonding the protein substances to the microparticles obtained in step (i) without surfactant.

Bioresorbable nonlamellar microparticles and uses thereof

The invention relates to a peptidic compound containing a polyprotein NS3/NS4 of a hepatitis C virus and a polypeptide NS5b of hepatitis C virus. Said invention also relates to expression vectors such as adenovirus and poxyvirus in which nucleic sequences coding for the polyprotein NS3/NS4 and the polypeptide NS5b. The inventive compound can be used for a therapeutic application.

Composition comprising the polyprotein NS3/NS4 and the polypeptide NS5B of HCV, expression vectors including the corresponding nucleic sequences and their therapeutic use

The present invention relates to an isolated fusion protein comprising at least three NS polypeptides originating from a hepatitis C virus which are configured in said fusion protein in an order which is distinct of the order in which they appear in the native configuration. The present invention also relates to a nucleic acid molecule encoding such a fusion protein and a vector comprising such a nucleic acid molecule. The present invention also provides infectious viral particles and host cells comprising such a nucleic acid molecule or such a vector. The present invention also relates to a method for recombinantly producing such a fusion protein. Finally, the present invention also provides a pharmaceutical composition comprising such a fusion protein, a nucleic acid molecule, a vector, infectious viral particles and a host cell as well as the therapeutic use thereof for treating or preventing HCV infections, HCV-associated diseases and pathologic conditions as well as a method of inducing or stimulating an immune response against HCV in a host organism.

Hepatitis C virus non structural fusion protein

Novel peptide compositions are described. In particular, peptide compositions are described which include at least two peptides which are selected from among the following peptides: a peptide A having at least the amino acid sequence of SEQ ID NO 1, a peptide B having at least the amino acid sequence of SEQ ID NO 45, a peptide C having at least the amino acid sequence of SEQ ID NO 127, and a peptide D having at least the amino acid sequence of SEQ ID NO 174. The compositions can be used, in particular, in the preparation of active pharmaceutical compositions against the hepatitis C virus.

Peptide compositions and their use against the hepatitis C virus

Peptide compositions are described. In particular, peptide compositions are described which include at least two peptides which are selected from among the following peptides: a peptide A having at least the amino acid sequence of SEQ ID N&#xb0; 1, a peptide B having at least the amino acid sequence of SEQ ID N&#xb0; 45, a peptide C having at least the amino acid sequence of SEQ ID N&#xb0; 127, and a peptide D having at least the amino acid sequence of SEQ ID N&#xb0; 174. The compositions can be used, in particular, in the preparation of active pharmaceutical compositions against the hepatitis C virus.

Nucleic acid compositions and their use against the hepatitic C virus

The invention relates to a peptidic compound containing a polyprotein NS3/NS4 of a hepatitis C virus and a polypeptide NS5b of hepatitis C virus. Said invention also relates to expression vectors such as adenovirus and poxvirus in which nucleic sequences coding for the polyprotein NS3/NS4 and the polypeptide NS5b. The inventive compound can be used for a therapeutic application.

The present invention relates to recombinant expression vectors which express segments of deoxyribonucleic acid that encode recombinant HIV and HCV antigens. These recombinant expression vectors are transformed into host cells and used in a method to express large quantities of these antigens. The invention also provides compositions containing certain of the isolated antigens, diagnostic systems containing these antigens and methods of assaying body fluids to detect the presence of antibodies against the antigens of the invention.

Method for detecting NANBV associated seroconversion

Described are novel antibodies specifically recognizing conformation dependent epitopes of HCV glycoprotein E2 and that are capable aof neutralizing the binding of E2 protein onto susceptible cells. Furthermore, antigens and epitopes recognized by the above-described antibodies as well as polynucleotides encoding said antibodies are provided. Also provided are to vectors comprising said polynucleotides as well as host cells transformed therewith and their use in the production of said antibodies. In addition, pharmaceutical and diagnostic compositions are provided comprising any of the aforedescribed antibodies, antigens, epitopes, polynucleotides, vectors or cells. Further described is the use of the aforementioned antibodies, antigens, polynucleotides and vectors in adoptive immunotherapy, preferably for the treatment or prevention of HCV infection during liver transplantation.

Anti hepatitis C virus antibody and uses thereof

The present invention relates to recombinant expression vectors which express segments of deoxyribonucleic acid that encode recombinant HIV and HCV antigens. These recombinant expression vectors are transformed into host cells and used in a method to express large quantities of these antigens. The invention also provides compositions containing certain of the isolated antigens., diagnostic systems containing these antigens and methods of assaying body fluids to detect the presence of antibodies against the antigens of the invention.

Methods and systems for producing recombinant viral antigens

Growing community of inventors

Lyons, France

Genevieve Inchauspe